Your browser doesn't support javascript.
loading
Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura.
Bjornsdottir, Gyda; Chalmer, Mona A; Stefansdottir, Lilja; Skuladottir, Astros Th; Einarsson, Gudmundur; Andresdottir, Margret; Beyter, Doruk; Ferkingstad, Egil; Gretarsdottir, Solveig; Halldorsson, Bjarni V; Halldorsson, Gisli H; Helgadottir, Anna; Helgason, Hannes; Hjorleifsson Eldjarn, Grimur; Jonasdottir, Adalbjorg; Jonasdottir, Aslaug; Jonsdottir, Ingileif; Knowlton, Kirk U; Nadauld, Lincoln D; Lund, Sigrun H; Magnusson, Olafur Th; Melsted, Pall; Moore, Kristjan H S; Oddsson, Asmundur; Olason, Pall I; Sigurdsson, Asgeir; Stefansson, Olafur A; Saemundsdottir, Jona; Sveinbjornsson, Gardar; Tragante, Vinicius; Unnsteinsdottir, Unnur; Walters, G Bragi; Zink, Florian; Rødevand, Linn; Andreassen, Ole A; Igland, Jannicke; Lie, Rolv T; Haavik, Jan; Banasik, Karina; Brunak, Søren; Didriksen, Maria; T Bruun, Mie; Erikstrup, Christian; Kogelman, Lisette J A; Nielsen, Kaspar R; Sørensen, Erik; Pedersen, Ole B; Ullum, Henrik; Masson, Gisli; Thorsteinsdottir, Unnur.
Afiliação
  • Bjornsdottir G; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. gyda.bjornsdottir@decode.is.
  • Chalmer MA; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark.
  • Stefansdottir L; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Skuladottir AT; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Einarsson G; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Andresdottir M; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Beyter D; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Ferkingstad E; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Gretarsdottir S; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Halldorsson BV; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Halldorsson GH; Reykjavik University, School of Technology, Reykjavik, Iceland.
  • Helgadottir A; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Helgason H; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Hjorleifsson Eldjarn G; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Jonasdottir A; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Jonasdottir A; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Jonsdottir I; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Knowlton KU; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Nadauld LD; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Lund SH; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Magnusson OT; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Melsted P; Intermountain Heart Institute, Salt Lake City, UT, USA.
  • Moore KHS; Intermountain Healthcare, Saint George, UT, USA.
  • Oddsson A; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Olason PI; Faculty of Physical Sciences, School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Sigurdsson A; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Stefansson OA; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Saemundsdottir J; School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
  • Sveinbjornsson G; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Tragante V; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Unnsteinsdottir U; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Walters GB; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Zink F; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Rødevand L; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Andreassen OA; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Igland J; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Lie RT; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Haavik J; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Banasik K; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Brunak S; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Didriksen M; NORMENT, Centre for Mental Disorders Research, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • T Bruun M; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Erikstrup C; Department of Health and Social Science, Centre for Evidence-Based Practice, Western Norway University of Applied Science, Bergen, Norway.
  • Kogelman LJA; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Nielsen KR; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Sørensen E; Department of Biomedicine, University of Bergen, Bergen, Norway.
  • Pedersen OB; Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.
  • Ullum H; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Masson G; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Thorsteinsdottir U; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Nat Genet ; 55(11): 1843-1853, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37884687
ABSTRACT
Migraine is a complex neurovascular disease with a range of severity and symptoms, yet mostly studied as one phenotype in genome-wide association studies (GWAS). Here we combine large GWAS datasets from six European populations to study the main migraine subtypes, migraine with aura (MA) and migraine without aura (MO). We identified four new MA-associated variants (in PRRT2, PALMD, ABO and LRRK2) and classified 13 MO-associated variants. Rare variants with large effects highlight three genes. A rare frameshift variant in brain-expressed PRRT2 confers large risk of MA and epilepsy, but not MO. A burden test of rare loss-of-function variants in SCN11A, encoding a neuron-expressed sodium channel with a key role in pain sensation, shows strong protection against migraine. Finally, a rare variant with cis-regulatory effects on KCNK5 confers large protection against migraine and brain aneurysms. Our findings offer new insights with therapeutic potential into the complex biology of migraine and its subtypes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enxaqueca com Aura / Epilepsia / Transtornos de Enxaqueca Limite: Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Islândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enxaqueca com Aura / Epilepsia / Transtornos de Enxaqueca Limite: Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Islândia